ars.els-cdn.com€¦ · Web view(203) Támez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB....

Rapid review comparing REcruitment in PRevention and ThErapy RCTs: The REPoRTER Study- supplementary tables

Table 1. Summary of data from preventative metformin RCT’s included in the review

StudyCONSORTDiagram? Approached Screened Eligible Refused consent Randomised

1 Ramachandran (2006) (1) Y 11001 10839 1332 . 5312 Knowler (2002) (2) Y 158183 30996 7525 . 38193 Li et al (1999) (3) N . 29938 . . 904 Lehtovirta (2001) (4) N . . 174 . 405 Charles (1998) (5) N . . . . 4576 Rodriguez-Moctezuma (2005) (6) N . . . . 23

Total 2 2 3 3 0 6


Table 2. Summary of data from metformin treatment RCT’s included in the reviewStudy CONSORT

Diagram?Approached Screened Eligible Refused consent Randomised

1 Charpentier (2001) (7) N . . . . 3792 Goldstein (2003) (8) N . 298 247 . 2473 DeFronzo (1995)a (9) N . 535 350 61 2894 Hermann (1994) (10) N . 165 . . 1445 Hoffmann (1997) (11) N . . . . 966 Chiasson (2001) (12) N . . . . 3247 Pavo (2003) (13) Y . 321 205 . 2058 Uehara (2001) (14) N . . . . 269 Noury (1991) (15) N . . . . 6010 Tessier (1999) (16) N . . . . 3911 Campbell (1994) (17) N . . . . 4812 Amador-Lincona (2000) (18) N . 68 59 9 5913 Dalzell (1986) (19) N . . . . 3314 Damsbo (1998) (20) N . . . . 1815 del Prato (2003) (21) N . . . . 72216 Dornan (1991) (22) N . . . . 6017 Grant (1996) (23) N . 75 . . 5218 Hällsten (2002) (24) N . . . . 4519 Horton (2000) (25) Y . 1451 701 . 70120 Lee & Morley (1998)a (26) N . . . . 1221 Lee & Morley (1998)b (26) N . . . . 4822 Mather (2001) (27) N . . . . 4423 Teupe (1991) (28) N . . . . 10024 Moses (1999) (29) N . 108 . . 8325 Inzucci (1998) (30) N . . . . 2926 Fanghanel (1996) (31) N . . . . 6027 Chow (1995) (32) N . 100 . . 55


28 Giugliano (1993) (33) N . . . . 5029 Aviles-Santa (1999)(34) N . . . . 4330 Grant (1991) (35) N . . . . 4131 Imano (1998) (36) N . . . . 14432 Johnson (1993) (37) N . . . . 833 Relimpio (1998) (38) N . . . . 6034 Schneider (1991) (39) N . . . . 4035 Willms (1999) (40) N . . . . 8936 Bosi (2009) (41) Y . . 745 . 39037 Derosa (2009) (42) Y . . . . 117938 Wulffele (2002) (43) N . . . 355 27139 Douek (2005) (44) Y 1150 . 731 61 18340 Fujioka (2005)a (45) N . . . . 24041 Fujioka (2005)b (45) N . . . . 74242 Garber (1997) (46) N . . . . 45143 Goldstein (2007) (47) Y . 3544 . . 109144 Hermann (2001) (48) N . . . . 3745 Iozzo (2003) (49) N . . . . 3046 Jadzinsky (2009) (50) Y 2936 1394 . . 130647 Lewin (2007) (51) Y . 741 607 . 60748 List (2009) (52) Y . 440 416 16 38949 Natali (2004) (53) N . 106 . . 7450 Perez (2009) (54) Y . 1436 . . 60051 Ryysy (2001) (55) N . . . . 8152 Viljanen (2005) (56) N . . . . 4553 Wolever (2000) (57) N . . . . 32454 UK Prospective Diabetes Study

(UKPDS) Group (1998) (58)Y . 4209 . . 1704

55 Rachmani (2002) (59) N . 471 . 32 39356 Cryer (2005) (60) N . . . . 9000


57 Kooy (2009) (61) Y . 745 . 355 39058 Garber (2003) (62) N . . . . 45159 Blonde (2002) (63) N . . . . 63960 Galani (2011) (64) N . . . . 4561 Kabadi (2006) (65) N . . . . 4662 Kvapil (2006) (66) Y . 456 . . 34163 Ushakova (2007) (67) Y . 393 . . 30864 Kokic (2003) (68) N . . . . 8765 Altuntas (2003) (69) N . . . . 6066 Gram (2011) (70) Y . . . . 37167 Vähätalo (2007) (71) N . . . . 5268 Strowig (2002) (72) N . . . . 9269 Yilmaz (2007) (73) N . . . . 66

TOTAL 15 2 20 9 7 69


Table 3. Summary of data for preventative exercise RCT’s included in the reviewStudy CONSORT

Diagram?Approached Screened Eligible Refused consent Randomised

1 Bo et al (2007) (74) Y 1877 1658 503 . 3752 Da Qing (1997) (75) N 126715 110660 577 . 5773 DPP (2002) (76) N 158183 30383 7525 . 38194 DPS (1999) (77) Y . . . . 5225 IDPP (2006) (1) Y 11001 10839 1332 . 5316 Oldroyd (2002) (78) Y 498 . 82 . 787 Wing (1998) (79) N . . . . 1548 Liao (2002) (80) N . 340 . . 749 Lindahl (1999) (81) N . 28000 650 . 30110 Mensink (2003) (82) N 6108 2820 385 . 11411 NAVIGATOR (83) Y . 43502 10664 853 915212 Smith (2005) (84) Y . 361662 . . 1286613 Barclay (2008) (85) Y 45 45 40 3 3714 Greaves (2008) (86) Y . 427 420 . 14115 Torgerson (2004) (87) N . 8360 . . 31116 Whittemore (2009) (88) Y . 101 88 30 5817 Absetz (2009) (89) N . 462 405 . 35218 Carr (2005) (90) N . . . . 64

TOTAL 9 7 14 12 3 18


Table 4. Summary of data for exercise treatment RCT’s included in the reviewStudy CONSORT

Diagram?Approached Screened Eligible Randomised Refused consent

1 Cuff (2003) (91) N . . . 28 .2 Dela (2004) (92) N . . . 24 .3 Dunstan (1998) (93) N . . . 27 .4 Dunstan (2002) (94) N . . . 36 .5 Loimaala (2003) (95) N . . . 48 .6 Boudou (2001) (96) N . . . 16 .7 Tessier (2000) (97) N . . . 45 .8 Tsujiuchi (2002) (98) N . . 554 36 .9 Wing (1988ab) (99) N . . . 30 .10 Dunstan (1997a) (100) N . 127 55 55 .11 Vanninen (1992) (101) N . 108 . 78 712 Belli (2011) (102) N . . . 24 .13 Bjorgaas (2005) (103) N . . . 29 .14 Giannopoulou (2005) (104) N . . . 40 .15 Jorge (2011) (105) N . . 83 48 .16 Kadoglou (2007)a (106) N . . . 62 .17 Kadoglou (2007)b (107) N . . . 100 .18 Kadoglou (2010) (108) N . . . 50 .19 Ku (2010) (109) N . . . 44 .20 Lambers (2008) (110) Y . 65 . 54 1121 Middlebrooke (2006) (111) N . . . 59 .22 Sigal (2007) (112) Y 2282 385 317 251 6823 Sridhar (2010) (113) N . . . 105 .24 Vancea (2009) (114) N . . . 40 .25 Verity (1989) (115) N . . . 10 .26 Wycherley (2008) (116) Y . 68 37 36 127 Arora (2009) (117) N . . . 30 .


28 Castaneda (2002) (118) Y 100 77 . 62 3629 Cheung (2009) (119) N . . . 40 .30 Balducci (2004) (120) N . . . 120 .31 Balducci (2010) (121) N . . . 82 .32 Balducci (2010) (122) Y . 691 646 606 4033 Cauza (2006) (123) N . . . 20 .34 Loimaala (2007) (124) N . . . 48 .35 Loimaala (2009) (125) N . . . 50 .36 Okada (2011) (126) N . . . 38 .37 Tokmakidis (2004) (127) N . . . 9 .38 McGavock (2004) (128) N . . . 28 .39 Wagner (2006) (129) N . 94 . 62 .40 Krousel-Wood (2008) (130) Y . 155 94 94 .41 Praet (2008) (131) Y . 533 251 92 .42 Marcus (2008) (132) N . . . 15 .43 Aylin (2009) (133) N . . . 38 .44 Church (2010) (134) Y . 2421 292 262 .45 Lucotti (2011) (135) N . . . 50 .46 Goldhaber-Fiebert (2003) (136) N . . . 75 .47 Argurs-Collins (1997) (137) N . 198 . 64 .48 Christian (2008) (138) Y . 322 310 310 .49 Dasgupta (2006) (139) Y . 97 76 42 2650 Di Loreto (2003) (140) N . . . 340 .51 Kim (2006) (141) N . . . 58 .52 Jakicac (2007) (142) N 28622 9045 6626 5145 .53 Mayer-Davis (2004) (143) N . 1406 1106 143 .54 Ménard (2005) (144) Y 418 195 72 72 .55 Brun (2008) (145) N . . . 25 .56 Kim (2006) (146) N . . . 73 .57 Kirk (2003) (147) Y . . . 70 .


58 Kirk (2009) (148) Y . 270 190 134 .59 Leehey (2009) (149) N . 20 13 13 .60 Tudor-Locke (2004) (150) Y . . 146 60 7761 van Rooijen (2004) (151) Y . 617 220 158 .62 Samaras (1997) (152) N . . . 26 .63 Kaplan (1985) (153) N . . . 65 .64 Kraus (2002) (154) N . . . 159 .65 Brooks (2007) (155) N . . . 62 .67 Piette (2011) (156) Y 5367 2528 423 339 .68 Kruse (2010) (157) Y 260 260 184 79 8669 Taylor (2009) (158) Y . 25 24 24 .70 Skoro-Kondzaetal (2009) (159) Y . . . 59 .71 Dutton (2008) (160) N 242 . . 96 14672 Dunstan (2006) (161) N 266 206 61 60 173 Engel (2006) (162) N . . . 57 .74 Two Feathers (2005) (163) N . . 300 151 .75 Keyserling (2002) (164) Y . 219 . 200 .76 Plotnikoff (2010) (165) Y . 712 . 287 42577 Davies (2008) (166) Y . . 1109 824 .78 Baum (2007) (167) N . . . 40 .79 Cauza (2005a) (168) N . . . 15 .80 Honkola (1997) (169) N . . . 38 .81 Skarfors (1987) (170) N . . . 9 .82 Ishii (1998) (171) N . . . 17 .83 Hanefeld (1991) (172) N . 1846 1139 1139 .84 De Greef (2010) (173) N 164 . 164 41 .85 De Greef (2011)a (174) N 86 . 86 67 1986 De Greef (2011)b (175) Y . 325 124 92 3287 Wisse (2010) (176) N . 1540 128 74 .

TOTAL 23 10 29 29 87 14


Table 5. List of metformin preventative RCT’s excluded from review and reasons for exclusionStudy Review Reason for exclusion

1 Chiasson (2002) (177) Yuen (2010) Not metformin monotherapy2 Fang (2004) (178) Yuen (2010) Missing full article3 Jarrett (1979) (179) Gillies (2007) Not metformin monotherapy4 Giuliano (1993) (180) Salpeter (2008) Not for the prevention of diabetes type II5 Moghetti (2000) (181) Salpeter (2008) PCOS6 Pasquali (2000) (182) Salpeter (2008) PCOS7 Freemark (2001) (183) Salpeter (2008) Paediatric sample8 Kay (2001) (184) Salpeter (2008) Adolescent sample9 Ng (2001) (185) Salpeter (2008) PCOS10 Kelly (2002) (186) Salpeter (2008) PCOS11 Kocak (2002) (187) Salpeter (2008) PCOS12 Sturrock (2002) (188) Salpeter (2008) PCOS13 Chou (2003) (189) Salpeter (2008) PCOS14 Baillargeon (2004) (190) Salpeter (2008) PCOS15 Gambineri (2004) (191) Salpeter (2008) PCOS16 Hoeger (2004) (192) Salpeter (2008) PCOS17 Rodriguez (2004) (193) Salpeter (2008) Not for the prevention of diabetes type II18 James (2005) (194) Salpeter (2008) Not for the prevention of diabetes type II19 Stakos (2005) (195) Salpeter (2008) Not for the prevention of diabetes type II20 Vitale (2005) (196) Salpeter (2008) Not for the prevention of diabetes type II21 Bridger (2006) (197) Salpeter (2008) Adolescent sample22 Fleming (2002) (198) Salpeter (2008) PCOS23 Srinivasan (2006) (199) Salpeter (2008) Paediatric sample24 Tang (2006) (200) Salpeter (2008) PCOS


Table 6. List of metformin treatment RCT’s excluded from review and reason for exclusionStudy Review Reason for exclusion

1 DeFronzo (1995)b (9) Calvo (2005) Not metformin monotherapy2 Turner (1998) (201) Calvo (2005) Not metformin monotherapy3 Collier (1989) (202) Calvo (2005), Gansevoort (2004) Not an RCT4 Pérez (1997) (203) Calvo (2005) Not available in English5 Yki-Järvinen (1992) (204) Rutten (2004) Not metformin monotherapy6 Yki-Järvinen (1999) (205) Rutten (2004), Gansevoort (2004) Not metformin monotherapy7 Bastyr (1999) (206) Rutten (2004) Not metformin monotherapy8 Calle-Pascual (1995) (207) Gansevoort (2004) Not metformin monotherapy9 Nagi (1993) (208) Gansevoort (2004) Not metformin monotherapy10 Robinson (1998) (209) Gansevoort (2004) Cross-over study11 Abbink (2002) (210) Gansevoort (2004) Cross-over study12 Chu (2002) (211) Gansevoort (2004) Not metformin monotherapy13 Groop (1989) (212) Gansevoort (2004) Not metformin monotherapy14 Hanefeld (1998) (213) Gansevoort (2004) Not available in English15 Hermann (1991) (214) Gansevoort (2004) Cross-over study16 Klein (1991) (215) Gansevoort (2004) Not metformin monotherapy17 Niazi (1998) (216) Gansevoort (2004) Not metformin monotherapy18 Rains (1988) (217) Gansevoort (2004) Cross-over study19 UK Prospective Diabetes Study Group (218) Gansevoort (2004), Cornu (2012) Not metformin monotherapy20 Wilson (1989) (219) Gansevoort (2004) Not metformin monotherapy21 Jacobson (2009) (220) Stevens (2012) Type 1 diabetes22 Khan (2006) (221) Stevens (2012) Cross-over study23 Lund (2008) (222) Stevens (2012) Type 1 diabetes24 Meyer (2002) (223) Stevens (2012) Type 1 diabetes25 Ponssen (2000) (224) Stevens (2012), Almdal (2012) Cross-over study26 Wild (2004) (225) Cornu (2012) Not an RCT27 Heine (1995) (226) Almdal (2012) Not metformin monotherapy28 Civera (2008) (227) Almdal (2012) Not metformin monotherapy29 Onuchin (2010) (228) Almdal (2012) Not available in English30 Kokic (2010) (229) Almdal (2012) Not using a human sample31 Cusi (1996) (230) Gansevoort (2004) Missing full article


32 Grant (1998) (231) Gansevoort (2004) Missing full article33 Schnack (1996) (232) Hemmingsen (2012) Missing full article34 Hirsch (1999) (233) Hemmingsen (2012) Missing full article35 South Danish Diabetes Study (234) Almdal (2012) Missing full article


Table 7. List of preventative exercise RCT’s excluded from review and reason for exclusionStudy Review Reason for exclusion

1 Kosaka (2005) (235) Orozco (2008), Madden (2005), Cardona-Morrell (2010) Not an RCT2 Jarrett (1979) (179) Norris (2005) No exercise noted in the intervention3 Hu (1999) (236) Madden (2008) Not an RCT4 STOP- NIDDM (237) Hooper (2011) No exercise noted in the intervention5 CANOE (238) Hooper (2011) No exercise noted in the intervention6 DREAM (239) Hooper (2011) No exercise noted in the intervention7 Kawamori (2009) (240) Hooper (2011) No exercise noted in the intervention8 Dyson (1997) (241) Norris (2005), Cardona-Morrell (2010) Missing full article9 Page (1992) (242) Norris (2005) Missing full article


Table 8. List of exercise treatment RCT’s excluded from review and reasons for exclusionStudy Review Reason for exclusion

1 Mourier (1997) (243) Thomas (2006), Boule (2009), Hayashino (2012), Snowling (2006), Boule (2001)

Not exercise

2 Ribeiro (2008) (244) Hayashino (2012), Umpierre (2011) Not an RCT3 Zois (2009) (245) Oliveira (2012) Not an RCT4 Kluding (2010) (246) Oliveira (2012) Not an RCT5 Segerstrӧm (2010) (247) Oliveira (2012) Not an RCT6 Touvra (2011) (248) Oliveira (2012) Not an RCT7 Diedrich (2010) (249) Umpierre (2011) Not an RCT8 Flegal (2000) (250) Kelley (2007) Not an RCT9 Keller (2001) (251) Kelley (2007) Not diabetes type II10 Sopko (1985) (252) Kelley (2007) Not diabetes type II11 Martyn-Nemeth (2010) (253) Plotnikoff (2013) Not an RCT12 Klug (2008) (254) Plotnikoff (2013) Not diabetes type II13 Boyd (2006) (255) Plotnikoff (2013) Not an RCT14 Brandon (2003) (256) Plotnikoff (2013) Not diabetes type II15 Less (2009) (257) Plotnikoff (2013) Not an RCT16 Lehmann (1995) (258) Snowling (2006), Boule (2001) Not an RCT17 Zapotoczky (2001) (259) Norris (2005) Not exercise18 Trento (2002) (260) Norris (2005) Not exercise19 Uusitupa (1993) (261) Norris (2005) Prevention study20 Hockaday (1978) (262) Norris (2005) No exercise21 Metz (2000) (263) Norris (2005) No exercise22 Milne (1994) (264) Norris (2005) No exercise23 Muchmore (1994) (265) Norris (2005) No exercise24 Pascale (1995) (266) Norris (2005) No exercise25 Wing (1986) (267) Norris (2005) No exercise26 Wing (1994) (268) Norris (2005) No exercise27 Baldi (2003) (269) Thomas (2006), Hayashino (2012), Irvine (2009), Snowling (2006) Missing full article28 Raz (1994) (270) Thomas (2006), Boule (2009), Umpierre (2011), Hayashino (2012),

Snowling (2006), Boule (2001)Missing full article

29 Ronnemaa (1986) (271) Thomas (2006), Hayashino (2012), Umpierre (2011), Snowling (2006), Missing full article


Boule (2001)30 Yeater (1990) (272) Thomas (2006), Boule (2003) Missing full article31 Vanninen (1993) (273) Boule (2003) Missing full article32 Gram (2011) (274) Hayashino (2012), Oliverira (2012), Avery (2012) Missing full article33 Ligtenberg (2006) (275) Hayashino (2012), Umpierre (2011), Kelley (2007), snowling (2006), Avery

(2012)Missing full article

34 Fatone (2010) (276) Oliveria (2012) Missing full article35 Ferrer-Garcia (2011) (277) Oliveria (2012) Missing full article36 Campbell (1968) (278) Kelley (2007) Missing full article37 Gillett (1995) (279) Kelley (2007) Missing full article38 Hagan (1986) (280) Kelley (2007) Missing full article39 Hinkleman (1993) (281) Kelley (2007) Missing full article40 Hopewell (1989) (282) Kelley (2007) Missing full article41 Leon (1996) (283) Kelley (2007) Missing full article42 Nieman (2002) (284) Kelley (2007) Missing full article43 Wood (1988) (285) Kelley (2007) Missing full article44 Sykes (2004) (286) Sukala (2012) Missing full article45 Plotnikoff (2011) (287) Plotnikoff (2012), Avery (2012) Missing full article46 Mathieu (2008) (288) Plotnikoff (2012) Missing full article47 Speer (2008) (289) Plotnikoff (2012) Missing full article48 Boudou (2000) (290) Snowling (2006) Missing full article49 Fujii (1982) (291) Snowling (2006), Boule (2001) Missing full article50 Khan (1995) (292) Snowling (2006) Missing full article51 Yamanouchi (1995) (293) Snowling (2006) Missing full article52 Heller (1988) (294) Norris (2005) Missing full article53 Korhonen (1987) (295) Norris (2005) Missing full article54 Pissarek (1980) (296) Norris (2005) Missing full article55 Sone (2002) (297) Norris (2005) Missing full article56 Wing (1985) (267;298) Norris (2005) Missing full article57 Wing (1991)a (299) Norris (2005) Missing full article58 Wing (1991)b (300) Norris (2005) Missing full article


Reference List

(1) Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modificationand metformin prevent type 2 diabetes in Asian Indian subjects with impairedglucose tolerance (IDPP-1). Diabetologia 2006;49(2):289-97.

(2) Knowler WC, Barrett-Connor E, Fowler S, Hamman RF, Lachin JM, Walker E ea. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Interventionor Metformin. N Engl J Med 2002;346(6):393-403.

(3) Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX ea. Effect of metformin on patients with impaired glucose tolerance. Diabet Med 1999;16:477-81.

(4) Lehtovirta M, Forsén B, Gullström M, Häggblom M, Eriksson JG, Taskinen MR, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001;18(7):578-83.

(5) Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998;21(11):1967-72.

(6) Rodriguez-Moctezuma JR, Robles-Lopez G, Lopez-Carmona JM, Gutierrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab 2005;7(2):189-92.

(7) Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapyin type 2 diabetic patients. Diabet Med 2001;18:828-34.

(8) Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneousglipizide/metformin as second-line pharmacologic treatment for patientswith type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890-903.

(9) deFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus.The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9.


(10) Hermann LS, Scherstén B, Bitzén PO, Kjellstöm T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-9.

(11) Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treatedNIDDM patients: the Essen-II Study. Am J Med 1997;103:483-90.

(12) Chiasson JL, Nadtich L, for the Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment oftype 2 diabetes. Diabetes Care 2001;24:989-94.

(13) Pavo I, Jermendy G, Varkonyi TT, erenyi Z, yimesi A, houstov S ea. Effect of pioglitazone compared with metformin on glycemic control and indicators ofinsulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin EndocrinolMetab 2003;88:1637-45.

(14) Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001;3:319-25.

(15) Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in thetreatment of NIDD. Diabete Metab. Diabete Metab 1991;17:209-12.

(16) Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidationmarkers in type 2 diabetes. Metabolism 1999;48:897-903.

(17) Campbell IW, Menzis DG, Chalmers J, McBain AM, Brown IRF. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 1994;20:394-400.

(18) Amador-Licona N, Guizar-Mendoza J, Vargas E, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res 2000;31:571-5.

(19) Dalzell GW, Hadden DR, Atkinson AB, Kennedy L, Weaver JA. A randomized trial tolbutamide and metformin for persistent severe hyperglycaemia in noninsulin dependent diabetes mellitus (NIDDM). Irish J Med Sci 1986;155:341-2.

(20) Damsbo P, Hermann LS, aag A, Hother-Nielsen O, Beck-Nielsen H. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obesepatients with NIDDM treated with diet and metformin. Diabetes Care 1998;21:1489-94.


(21) del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol 2003;40:20-7.

(22) Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-4.

(23) Grant P. The effects of high- and medium-dose metformin therapy on cardiovascular risk factorsin patients with type II diabetes. Diabetes Care 1996;19:64-6.

(24) Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T ea. Rosiglitazone but not metformin enhances insulin-and exercise-stimulated skeletal muscleglucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479-85.

(25) Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.

(26) Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesitywith obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53.

(27) Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37(1344):1350.

(28) Teupe B, Bergis K. Prospective randomized two-years clinical study comparing additional metformintreatment with reducing diet in type 2 diabetes. Diabetes Metab 1991;17:213-7.

(29) Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patientswith type 2 diabetes. Diabetes Care 1999;22:119-24.

(30) Inzucchi SE, aggs DG, pollett GR, age SL, ife FS, alton V ea. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.

(31) Fanghanel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin´s effects on glucose and lipid metabolism in patients with secondary failure tosulphonylureas. Diabetes Care 1996;19:1185-9.


(32) Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in thetreatment of secondary failure in NIDDM patients. Diabetes Care 1995;18(3):307-14.

(33) Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic controland reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.

(34) Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetesmellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-8.

(35) Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activatorinhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-5.

(36) Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-9.

(37) Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993;42:1217-22.

(38) Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlledtype 2 diabetes mellitus: an open-label randomized trial. Diabet Med 1998;15:997-1002.

(39) Schneider J. Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabet Metab 1991;17:185-90.

(40) Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficientlycontrolled with diet and sulphonylureas: a randomized, placebocontrolled study. Diabet Med 1999;16:755-61.

(41) Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;5:506-15.

(42) Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. Metabolism 2009;58(8):1059-66.

(43) Wulffele MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133-40.


(44) Douek IF, llen SE, wings P, Gale EAM, etformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double blind randomized placebo controlled trial. Diabet Med 2005;22(5):634-40.

(45) Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, et al. Efficacy, dose response relationship and safety of once daily extended release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double blind, placebo controlled studies. Diabetes Obes Metab 2005;7(1):28-39.

(46) Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double blind, placebo controlled, dose response trial. Am J Med 1997;103(6):491-7.

(47) Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase?4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87.

(48) Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O, et al. Long term glycaemic improvement after addition of metformin to insulin in insulin treated obese type 2 diabetes patients. Diabetes Obes Metab 2001;3(6):428-34.

(49) Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, et al. Effects of metformin and rosiglitazone monotherapy on insulin?mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003;26(7):2069-74.

(50) Jadzinsky M, Pfützner A, Paz Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-22.

(51) Lewin A, Lipetz R, Wu J, Schwartz S. Comparison of extended release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, doubleblind, randomized, controlled, phase III study. Clin Ther 2007;29(5):844-55.

(52) List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32(4):650-7.

(53) Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27(6):1349-57.


(54) Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed?dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25(12):2915-23.

(55) Ryysy L, Yki Järvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE?selectin concentrations in type 2 diabetes. Diabetes Care 2001;24(3):549-54.

(56) Viljanen AP, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, et al. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a doubleblind, randomized study with metformin. J Clin Endocrinol Metab 2005;90(12):6523-8.

(57) Wolever TMS, Assiff L, Basu T.et al. Miglitol, an (alpha) glucosidase inhibitor, prevents the metformininduced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutr Res 2000;20(10):1447-56.

(58) UK Prospective Diabetes Study Group. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treatedtype 2 diabetes (UKPDS 28). Diabetes Care 1998;21:87-92.

(59) Rachmani R, Slavachevski I, evi Z, Zadok B, edar Y ea. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002;13:428-33.

(60) Cryer D, Mills D, Nicholas SP, Stadel BV, Henry DH. Comparative outcomes study of metformin intervention versus conventional approach. Diabetes Care 2005;28:539-43.

(61) Kooy A, De Jager J, Lehert P, Bets D, Wulffele´ MG ea. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-25.

(62) Garber AJ, Donovan DS, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-604.

(63) Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylureas therapy. Diabetes Obes Metab 2002;4:368-75.

(64) Galani V, Patel HM. Comparison of metformin and insulin monotherapy with combined metformin and insulin therapy in patients of type 2 diabetes with HbA1c > 7%. Int J Pharmaceutical Biol Arch 2011;2:563-8.


(65) Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabet Res Clin Pract 2006;72:265-70.

(66) Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabet Obes Metab 2006;8:39-48.

(67) Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O. Comparison of biphasic insulin aspart 30 given three times daily or twice daily incombination with metformin versus oral antidiabetic drugs alone in patients with poorlycontrolled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trialconducted in Russia. Clin Ther 2007;29:2374-84.

(68) Kokic S, Bukovic D, Radman M, Capkun V, Gabric N, Lesko V ea. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Collegium Antropologicum 2003;27:181-7.

(69) Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O ea. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabet Obes Metab 2003;5:371-8.

(70) Gram B, Christensen R, Christiansen C, Gram J. Effects of nordic walking and exercise in type 2 diabetes mellitus: a randomized controlled trial. Clin J Sport Med 2010;20(5):355-61.

(71) Vähätalo M, Rönnemaa T, Viikari J. Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scand J Prim Health Care 2007;25:147-53.

(72) Strowig SM, Avilés-Santa ML, askin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691-8.

(73) Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Acta Diabetologica 2007;44:187-92.

(74) Bo S, Ciccone G, Baldi C, Benini L, Dusio F, Forastiere G, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med 2007 Dec;22(12):1695-703.

(75) Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997 Apr;20(4):537-44.


(76) The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002 Dec;25(12):2165-71.

(77) Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999 Jul;42(7):793-801.

(78) Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Res Clin Pract 2001 Apr;52(1):29-43.

(79) Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998 Mar;21(3):350-9.

(80) Liao D, Asberry PJ, Shofer JB, Callahan H, Matthys C, Boyko EJ, et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care 2002 Sep;25(9):1504-10.

(81) Lindahl B, Nilsson TK, Jansson JH, Asplund K, Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 1999 Jul;246(1):105-12.

(82) Mensink M, Corpeleijn E, Feskens EJ, Kruijshoop M, Saris WH, de Bruin TW, et al. Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003 Jul;61(1):49-58.

(83) Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 Apr 22;362(16):1463-76.

(84) Davey SG, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005 Mar 1;142(5):313-22.

(85) Barclay C, Procter KL, Glendenning R, Marsh P, Freeman J, Mathers N. Can type 2 diabetes be prevented in UK general practice? A lifestyle-change feasibility study (ISAIAH). Br J Gen Pract 2008 Aug;58(553):541-7.

(86) Greaves CJ, Middlebrooke A, O'Loughlin L, Holland S, Piper J, Steele A, et al. Motivational interviewing for modifying diabetes risk: a randomised controlled trial. Br J Gen Pract 2008 Aug;58(553):535-40.


(87) Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan;27(1):155-61.

(88) Whittemore R, Melkus G, Wagner J, Dziura J, Northrup V, Grey M. Translating the diabetes prevention program to primary care: a pilot study. Nurs Res 2009 Jan;58(1):2-12.

(89) Absetz P, Oldenburg B, Hankonen N, Valve R, Heinonen H, Nissinen A, et al. Type 2 diabetes prevention in the real world: three-year results of the GOAL lifestyle implementation trial. Diabetes Care 2009 Aug;32(8):1418-20.

(90) Carr DB, Utzschneider KM, Boyko EJ, Asberry PJ, Hull RL, Kodama K, et al. A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function. Diabetes 2005 Feb;54(2):340-7.

(91) Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 2003 Nov;26(11):2977-82.

(92) Dela F, von Linstow ME, Mikines KJ, Galbo H. Physical training may enhance beta-cell function in type 2 diabetes. Am J Physiol Endocrinol Metab 2004 Nov;287(5):E1024-E1031.

(93) Dunstan DW, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG. Effects of a short-term circuit weight training program on glycaemic control in NIDDM. Diabetes Res Clin Pract 1998 Apr;40(1):53-61.

(94) Dunstan DW, Daly RM, Owen N, Jolley D, de Court, Shaw J, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 2002 Oct;25(10):1729-36.

(95) Loimaala A, Huikuri HV, Koobi T, Rinne M, Nenonen A, Vuori I. Exercise training improves baroreflex sensitivity in type 2 diabetes. Diabetes 2003 Jul;52(7):1837-42.

(96) Boudou P, de KE, Erlich D, Vexiau P, Gautier JF. Exercise training-induced triglyceride lowering negatively correlates with DHEA levels in men with type 2 diabetes. Int J Obes Relat Metab Disord 2001 Aug;25(8):1108-12.

(97) Tessier D, Menard J, Fulop T, Ardilouze J, Roy M, Dubuc N, et al. Effects of aerobic physical exercise in the elderly with type 2 diabetes mellitus. Arch Gerontol Geriatr 2000 Oct 1;31(2):121-32.


(98) Tsujiuchi T, Kumano H, Yoshiuchi K, He D, Tsujiuchi Y, Kuboki T, et al. The effect of Qi-gong relaxation exercise on the control of type 2 diabetes mellitus: a randomized controlled trial. Diabetes Care 2002 Jan;25(1):241-2.

(99) Wing RR, Epstein LH, Paternostro-Bayles M, Kriska A, Nowalk MP, Gooding W. Exercise in a behavioural weight control programme for obese patients with Type 2 (non-insulin-dependent) diabetes. Diabetologia 1988 Dec;31(12):902-9.

(100) Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care 1997 Jun;20(6):913-21.

(101) Vanninen E, Uusitupa M, Siitonen O, Laitinen J, Lansimies E. Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention. Diabetologia 1992 Apr;35(4):340-6.

(102) Belli T, Ribeiro LF, Ackermann MA, Baldissera V, Gobatto CA, Galdino da SR. Effects of 12-week overground walking training at ventilatory threshold velocity in type 2 diabetic women. Diabetes Res Clin Pract 2011 Sep;93(3):337-43.

(103) Bjorgaas M, Vik JT, Saeterhaug A, Langlo L, Sakshaug T, Mohus RM, et al. Relationship between pedometer-registered activity, aerobic capacity and self-reported activity and fitness in patients with type 2 diabetes. Diabetes Obes Metab 2005 Nov;7(6):737-44.

(104) Giannopoulou I, Fernhall B, Carhart R, Weinstock RS, Baynard T, Figueroa A, et al. Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism 2005 Jul;54(7):866-75.

(105) Jorge ML, de Oliveira VN, Resende NM, Paraiso LF, Calixto A, Diniz AL, et al. The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus. Metabolism 2011 Sep;60(9):1244-52.

(106) Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, et al. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil 2007 Dec;14(6):837-43.

(107) Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2007 Sep;30(9):2242-4.

(108) Kadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, et al. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab 2010 Apr;36(2):144-51.


(109) Ku YH, Han KA, Ahn H, Kwon H, Koo BK, Kim HC, et al. Resistance exercise did not alter intramuscular adipose tissue but reduced retinol-binding protein-4 concentration in individuals with type 2 diabetes mellitus. J Int Med Res 2010 May;38(3):782-91.

(110) Lambers S, Van LC, Van AK, Calders P. Influence of combined exercise training on indices of obesity, diabetes and cardiovascular risk in type 2 diabetes patients. Clin Rehabil 2008 Jun;22(6):483-92.

(111) Middlebrooke AR, Elston LM, Macleod KM, Mawson DM, Ball CI, Shore AC, et al. - Six months of aerobic exercise does not improve microvascular function in type 2 diabetes mellitus.

(112) Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud'homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007 Sep 18;147(6):357-69.

(113) Sridhar B, Haleagrahara N, Bhat R, Kulur AB, Avabratha S, Adhikary P. Increase in the heart rate variability with deep breathing in diabetic patients after 12-month exercise training. Tohoku J Exp Med 2010 Feb;220(2):107-13.

(114) Vancea DM, Vancea JN, Pires MI, Reis MA, Moura RB, Dib SA. Effect of frequency of physical exercise on glycemic control and body composition in type 2 diabetic patients. Arq Bras Cardiol 2009 Jan;92(1):23-30.

(115) Verity LS, Ismail AH. Effects of exercise on cardiovascular disease risk in women with NIDDM. Diabetes Res Clin Pract 1989 Jan 3;6(1):27-35.

(116) Wycherley TP, Brinkworth GD, Noakes M, Buckley JD, Clifton PM. Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. Diabetes Obes Metab 2008 Nov;10(11):1062-73.

(117) Arora E, Shenoy S, Sandhu JS. Effects of resistance training on metabolic profile of adults with type 2 diabetes. Indian J Med Res 2009 May;129(5):515-9.

(118) Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002 Dec;25(12):2335-41.

(119) Cheung NW, Cinnadaio N, Russo M, Marek S. A pilot randomised controlled trial of resistance exercise bands in the management of sedentary subjects with type 2 diabetes. Diabetes Res Clin Pract 2009 Mar;83(3):e68-e71.

(120) Balducci S, Leonetti F, Di MU, Fallucca F. Is a long-term aerobic plus resistance training program feasible for and effective on metabolic profiles in type 2 diabetic patients? Diabetes Care 2004 Mar;27(3):841-2.


(121) Balducci S, Zanuso S, Nicolucci A, Fernando F, Cavallo S, Cardelli P, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 2010 Oct;20(8):608-17.

(122) Balducci S, Zanuso S, Nicolucci A, De FP, Cavallo S, Cardelli P, et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2010 Nov 8;170(20):1794-803.

(123) Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P. The metabolic effects of long term exercise in Type 2 Diabetes patients. Wien Med Wochenschr 2006 Sep;156(17-18):515-9.

(124) Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Vuori I. Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. Cardiovasc Ultrasound 2007 Sep 26;5:32.:32.

(125) Loimaala A, Groundstroem K, Rinne M, Nenonen A, Huhtala H, Parkkari J, et al. Effect of long-term endurance and strength training on metabolic control and arterial elasticity in patients with type 2 diabetes mellitus. Am J Cardiol 2009 Apr 1;103(7):972-7.

(126) Okada S, Hiuge A, Makino H, Nagumo A, Takaki H, Konishi H, et al. Effect of exercise intervention on endothelial function and incidence of cardiovascular disease in patients with type 2 diabetes. J Atheroscler Thromb 2010 Aug 31;17(8):828-33.

(127) Tokmakidis SP, Zois CE, Volaklis KA, Kotsa K, Touvra AM. The effects of a combined strength and aerobic exercise program on glucose control and insulin action in women with type 2 diabetes. Eur J Appl Physiol 2004 Aug;92(4-5):437-42.

(128) McGavock J, Mandic S, Lewanczuk R, Koller M, Muhll IV, Quinney A, et al. Cardiovascular adaptations to exercise training in postmenopausal women with type 2 diabetes mellitus. Cardiovasc Diabetol 2004 Mar 15;3:3.:3.

(129) Wagner H, Degerblad M, Thorell A, Nygren J, Stahle A, Kuhl J, et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care 2006 Jul;29(7):1471-7.

(130) Krousel-Wood MA, Berger L, Jiang X, Blonde L, Myers L, Webber L. Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial. Diabetes Res Clin Pract 2008 Feb;79(2):230-6.

(131) Praet SF, van Rooij ES, Wijtvliet A, Boonman-de Winter LJ, Enneking T, Kuipers H, et al. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2008 May;51(5):736-46.


(132) Marcus RL, Smith S, Morrell G, Addison O, Dibble LE, Wahoff-Stice D, et al. Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus. Phys Ther 2008 Nov;88(11):1345-54.

(133) Aylin K, Arzu D, Sabri S, Handan TE, Ridvan A. The effect of combined resistance and home-based walking exercise in type 2 diabetes patients. Int J Diabetes Dev Ctries 2009 Oct;29(4):159-65.

(134) Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 2010 Nov 24;304(20):2253-62.

(135) Lucotti P, Monti LD, Setola E, Galluccio E, Gatti R, Bosi E, et al. Aerobic and resistance training effects compared to aerobic training alone in obese type 2 diabetic patients on diet treatment. Diabetes Res Clin Pract 2011 Dec;94(3):395-403.

(136) Goldhaber-Fiebert JD, Goldhaber-Fiebert SN, Tristan ML, Nathan DM. Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetic patients in rural Costa Rica. Diabetes Care 2003 Jan;26(1):24-9.

(137) Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL. A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects. Diabetes Care 1997 Oct;20(10):1503-11.

(138) Christian JG, Bessesen DH, Byers TE, Christian KK, Goldstein MG, Bock BC. Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. Arch Intern Med 2008 Jan 28;168(2):141-6.

(139) Dasgupta K, Grover SA, Da CD, Lowensteyn I, Yale JF, Rahme E. Impact of modified glucose target and exercise interventions on vascular risk factors. Diabetes Res Clin Pract 2006 Apr;72(1):53-60.

(140) Di LC, Fanelli C, Lucidi P, Murdolo G, De CA, Parlanti N, et al. Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care 2003 Feb;26(2):404-8.

(141) Kim CJ, Kang DH. Utility of a Web-based intervention for individuals with type 2 diabetes: the impact on physical activity levels and glycemic control. Comput Inform Nurs 2006 Nov;24(6):337-45.

(142) Jakicic JM, Jaramillo SA, Balasubramanyam A, Bancroft B, Curtis JM, Mathews A, et al. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. Int J Obes (Lond) 2009 Mar;33(3):305-16.


(143) Mayer-Davis EJ, D'Antonio AM, Smith SM, Kirkner G, Levin MS, Parra-Medina D, et al. Pounds off with empowerment (POWER): a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. Am J Public Health 2004 Oct;94(10):1736-42.

(144) Menard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005 Dec 6;173(12):1457-66.

(145) Brun JF, Bordenave S, Mercier J, Jaussent A, Picot MC, Prefaut C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: a one-year controlled randomized trial. Diabetes Metab 2008 Jun;34(3):258-65.

(146) Kim SH, Lee SJ, Kang ES, Kang S, Hur KY, Lee HJ, et al. Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 2006 Aug;55(8):1053-9.

(147) Kirk A, Mutrie N, MacIntyre P, Fisher M. Increasing physical activity in people with type 2 diabetes. Diabetes Care 2003 Apr;26(4):1186-92.

(148) Kirk A, Barnett J, Leese G, Mutrie N. A randomized trial investigating the 12-month changes in physical activity and health outcomes following a physical activity consultation delivered by a person or in written form in Type 2 diabetes: Time2Act. Diabet Med 2009 Mar;26(3):293-301.

(149) Leehey DJ, Moinuddin I, Bast JP, Qureshi S, Jelinek CS, Cooper C, et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol 2009 Dec 9;8:62. doi: 10.1186/1475-2840-8-62.:62-8.

(150) Tudor-Locke C, Bell RC, Myers AM, Harris SB, Ecclestone NA, Lauzon N, et al. Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes. Int J Obes Relat Metab Disord 2004 Jan;28(1):113-9.

(151) van Rooijen AJ, Rheeder P, Eales CJ, Becker PJ. Effect of exercise versus relaxation on haemoglobin A1C in Black females with type 2 diabetes mellitus. QJM 2004 Jun;97(6):343-51.

(152) Samaras K, Ashwell S, Mackintosh AM, Fleury AC, Campbell LV, Chisholm DJ. Will older sedentary people with non-insulin-dependent diabetes mellitus start exercising? A health promotion model. Diabetes Res Clin Pract 1997 Aug;37(2):121-8.

(153) Kaplan RM, Wilson DK, Hartwell SL, Merino KL, Wallace JP. Prospective evaluation of HDL cholesterol changes after diet and physical conditioning programs for patients with type II diabetes mellitus. Diabetes Care 1985 Jul;8(4):343-8.


(154) Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002 Nov 7;347(19):1483-92.

(155) Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME, Castaneda-Sceppa C. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. Int J Med Sci 2006 Dec 18;4(1):19-27.

(156) Piette JD, Richardson C, Himle J, Duffy S, Torres T, Vogel M, et al. A randomized trial of telephonic counseling plus walking for depressed diabetes patients. Med Care 2011 Jul;49(7):641-8.

(157) Kruse RL, Lemaster JW, Madsen RW. Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy: "feet first" randomized controlled trial. Phys Ther 2010 Nov;90(11):1568-79.

(158) Taylor JD, Fletcher JP, Tiarks J. Impact of physical therapist-directed exercise counseling combined with fitness center-based exercise training on muscular strength and exercise capacity in people with type 2 diabetes: a randomized clinical trial. Phys Ther 2009 Sep;89(9):884-92.

(159) Skoro-Kondza L, Tai SS, Gadelrab R, Drincevic D, Greenhalgh T. Community based yoga classes for type 2 diabetes: an exploratory randomised controlled trial. BMC Health Serv Res 2009 Feb;%19;9:33. doi: 10.1186/1472-6963-9-33.:33-9.

(160) Dutton GR, Provost BC, Tan F, Smith D. A tailored print-based physical activity intervention for patients with type 2 diabetes. Prev Med 2008 Oct;47(4):409-11.

(161) Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care 2006 Dec;29(12):2586-91.

(162) Engel L, Lindner H. Impact of using a pedometer on time spent walking in older adults with type 2 diabetes. Diabetes Educ 2006 Jan;32(1):98-107.

(163) Two FJ, Kieffer EC, Palmisano G, Anderson M, Sinco B, Janz N, et al. Racial and Ethnic Approaches to Community Health (REACH) Detroit partnership: improving diabetes-related outcomes among African American and Latino adults. Am J Public Health 2005 Sep;95(9):1552-60.

(164) Keyserling TC, Samuel-Hodge CD, Ammerman AS, Ainsworth BE, Henriquez-Roldan CF, Elasy TA, et al. A randomized trial of an intervention to improve self-care behaviors of African-American women with type 2 diabetes: impact on physical activity. Diabetes Care 2002 Sep;25(9):1576-83.

(165) Plotnikoff RC, Eves N, Jung M, Sigal RJ, Padwal R, Karunamuni N. Multicomponent, home-based resistance training for obese adults with type 2 diabetes: a randomized controlled trial. Int J Obes (Lond) 2010 Dec;34(12):1733-41.


(166) Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008 Mar 1;336(7642):491-5.

(167) Baum K, Votteler T, Schiab J. Efficiency of vibration exercise for glycemic control in type 2 diabetes patients. Int J Med Sci 2007 May 31;4(3):159-63.

(168) Cauza E, Hanusch-Enserer U, Strasser B, Kostner K, Dunky A, Haber P. Strength and endurance training lead to different post exercise glucose profiles in diabetic participants using a continuous subcutaneous glucose monitoring system. Eur J Clin Invest 2005 Dec;35(12):745-51.

(169) Honkola A, Forsen T, Eriksson J. Resistance training improves the metabolic profile in individuals with type 2 diabetes. Acta Diabetol 1997 Dec;34(4):245-8.

(170) Skarfors ET, Wegener TA, Lithell H, Selinus I. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men. A feasibility study over 2 years. Diabetologia 1987 Dec;30(12):930-3.

(171) Ishii T, Yamakita T, Sato T, Tanaka S, Fujii S. Resistance training improves insulin sensitivity in NIDDM subjects without altering maximal oxygen uptake. Diabetes Care 1998 Aug;21(8):1353-5.

(172) Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991 Apr;14(4):308-17.

(173) De GK, Deforche B, Tudor-Locke C, De B, I. - A cognitive-behavioural pedometer-based group intervention on physical activity and sedentary behaviour in individuals with type 2 diabetes.

(174) De GK, Deforche B, Tudor-Locke C, De B, I. Increasing physical activity in Belgian type 2 diabetes patients: a three-arm randomized controlled trial. Int J Behav Med 2011 Sep;18(3):188-98.

(175) De Greef KP, Deforche BI, Ruige JB, Bouckaert JJ, Tudor-Locke CE, Kaufman JM, et al. The effects of a pedometer-based behavioral modification program with telephone support on physical activity and sedentary behavior in type 2 diabetes patients. Patient Educ Couns 2011 Aug;84(2):275-9.

(176) Wisse W, Rookhuizen MB, de Kruif MD, van RJ, Jordans I, ten CH, et al. Prescription of physical activity is not sufficient to change sedentary behavior and improve glycemic control in type 2 diabetes patients. Diabetes Res Clin Pract 2010 May;88(2):e10-e13.


(177) Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun 15;359(9323):2072-7.

(178) Fang Y, Li T, Chen S. Effect of medicine and non-medicine intervention onthe outcomes of patients with impaired glucose tolerance - 5-year follow-up. Zhongguo Linchuang Kangfu 2004;8:6562-3.

(179) Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia 1979 Jan;16(1):25-30.

(180) Giugliano D, De RN, Di MG, Marfella R, Acampora R, Buoninconti R, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993 Oct;16(10):1387-90.

(181) Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. - Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

(182) Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. - Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

(183) Freemark M, Bursey D. - The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Peadiatrics 2000.

(184) Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001 Dec;50(12):1457-61.

(185) Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001 Aug;16(8):1625-31.

(186) Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002 Aug;147(2):217-21.

(187) Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002 Jan;77(1):101-6.


(188) Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002 May;53(5):469-73.

(189) Chou KH, von Eye CH, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003 Feb;35(2):86-91.

(190) Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004 Oct;82(4):893-902.

(191) Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004 Feb;60(2):241-9.

(192) Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004 Aug;82(2):421-9.

(193) Rodriguez Y, Giri M, Feyen E, Christophe AB. Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals. Prostaglandins Leukot Essent Fatty Acids 2004 Dec;71(6):391-7.

(194) James AP, Watts GF, Mamo JC. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes Obes Metab 2005 Jul;7(4):381-9.

(195) Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005 May;91(5):589-94.

(196) Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005 Sep;258(3):250-6.

(197) Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006 Mar;160(3):241-6.

(198) Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002 Feb;87(2):569-74.


(199) Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006 Jun;91(6):2074-80.

(200) Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006 Jan;21(1):80-9.

(201) Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE ea, et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34). Lancet 1998;352:854-65.

(202) Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregabilityin recently diagnosed type 2 (noninsulin-dependent) diabetic patients. Diabete Metab 1989;15:420-5.

(203) Támez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB. Normoglucemia en diabetes mellitus no dependiente de insulina de reciente diagnóstico. Tratamiento no farmacológico vs. tratamiento farmacológico. Med Int Mex 1997;13:272-5.

(204) Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L ea. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine 1992;327(20):1426-33.

(205) Yki-Järvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M 1999. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Annals of Internal Medicine 1999;130(5):389-96.

(206) Bastyr EJ, Johnson ME, Trautmann ME, Anderson JH, Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agentfailure. Clinical Therapeutics 1999;21(10):1703-14.

(207) Calle-Pascual AL, Garcia-Honduvilla J, artin-Alvarez PJ et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabeticpatients with secondary failure to sulfonylurea treatment. Diabet Metab 1995;21:256-60.

(208) Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, andplasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:621-9.

(209) Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDMpatients with suboptimal metabolic control. Diabetes Care 1998;21:701-5.


(210) Abbink EJ, Pickkers P, van Rosendaal AJ et al. Vascular effects of glibenclamide vs. glimepiride and metformin in type 2 diabetic patients. Diabet Med 2002;19:136.

(211) Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patientswith type 2 diabetes. Diabetes Care 2002;25:542-9.

(212) Groop L, Widen E, Franssila-Kallunki A et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:599-605.

(213) Hanefeld M, Bar K. Effizienz und Sicherheit der Kombinationsbehandlung von Typ-2-Diabetikern mit Acarboseund Metformin. Diabetes und Stoffwechsel 1998;7:186-90.

(214) Hermann LS, Karlsson JE, Sjostrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide withspecial reference to lipid profiles. Eur J Clin Pharmacol 1991;41:263-5.

(215) Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondaryfailures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabet Metab 1991;17:235-40.

(216) Niazi R, Muzaffar Z. Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondarysulphonylurea failure in obese type II (NIDDM) patients. JPMA J Pak Med Assoc 1998;48:336-8.

(217) Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 1988;5:653-8.

(218) UK Prospective Diabetes Study (UKPDS) Group. Effect of Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

(219) Wilson JA, Scott MM, Gray RS. A comparison of metformin versus guar in combination with sulphonylureas in the treatmentof non-insulin dependent diabetes. Horm Metab Res 1989;21:317-9.

(220) Jacobsen IB, Henriksen JE, Beck Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 2009;105(3):145-9.


(221) Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabet Med 2006;23(10):1079-84.

(222) Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment in patients with type 1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 2008;3(10):e3363.

(223) Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002;25(12):2153-8.

(224) Ponssen HH, Elte JW, Lehert P, Schouten JP, Bets D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000;22(6):709-18.

(225) Wild S, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.

(226) Heine RJ, Scheen A, n Gaal L, Schmitt H, Van der Waal PS. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure on oral hypoglycaemic agent. Neth J Med 1995;47:A59-60.

(227) Civera M SJ, Merchante A, Salvador M, Martínez I. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. Diabet Res Clin Pract 2008;79:42-7.

(228) Onuchin SG, lsukova OS, olov'ev OV, Onuchina EL. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus.] [In Russian.]. Terapevticheskii Arkhiv 2010;(82):34-41.

(229) Kokic S, Kokic V, Krnic M, Miric L, Jovanovic Z, Orlic-Crncevic Z. Advantage of prandial insulin as a therapeutic approach in initial secondary pancreatic beta-cell exhaustion in type 2 diabetic patients. Diabetologia Croatica 2010;39:37-42.

(230) Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependentdiabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.

(231) Grant PJ. Metformin reduces circulating factor VII concentrations in patients with type 2 diabetesmellitus [letter]. Thromb Haemost 1998;80:209-10.


(232) Schnack C, Biesenbach G, Kacerovsky G, Mihaljevic R, Pecnik I, Pieber T ea. Evaluation of optimal therapy in type-2 diabetic patients insufficiently treated with sulfonylureas: the Austrian insulin intervention study. Diabetologia 1996;39(1):A33.

(233) Hirsch IB. Metformin added to insulin therapy in poorly controlled type 2 diabetes. Diabetes Care 1999;22:854.

(234) South Danish Diabetes Study. Evaluation of the antidiabetic treatment of type 2 diabetes mellitus (SDDS). http://clinicaltrials gov/ct2/show/NCT00121966 2011.

(235) Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005 Feb;67(2):152-62.

(236) Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999 Oct;%20;282(15):1433-9.

(237) Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003 Dec;26(12):3230-6.

(238) Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 Jul 10;376(9735):103-11.

(239) Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23;368(9541):1096-105.

(240) Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009 May 9;373(9675):1607-14.

(241) Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC. The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 1997 Dec;46(12 Suppl 1):50-5.

(242) Page RC, Harnden KE, Cook JT, Turner RC. Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med 1992 Jul;9(6):562-6.

(243) Mourier A, Gautier JF, de KE, Bigard AX, Villette JM, Garnier JP, et al. Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branched-chain amino acid supplements. Diabetes Care 1997 Mar;20(3):385-91.

http://clinicaltrials/


(244) Ribeiro IC, Iborra RT, Neves MQ, Lottenberg SA, Charf AM, Nunes VS, et al. HDL atheroprotection by aerobic exercise training in type 2 diabetes mellitus. Med Sci Sports Exerc 2008 May;40(5):779-86.

(245) Zois C, Tokmakidis SP, Volaklis KA, Kotsa K, Touvra AM, Douda E, et al. Lipoprotein profile, glycemic control and physical fitness after strength and aerobic training in post-menopausal women with type 2 diabetes. Eur J Appl Physiol 2009 Aug;106(6):901-7.

(246) Kluding PM, Singh R, Goetz J, Rucker J, Bracciano S, Curry N. Feasibility and effectiveness of a pilot health promotion program for adults with type 2 diabetes: lessons learned. Diabetes Educ 2010 Jul;36(4):595-602.

(247) Segerstrom AB, Glans F, Eriksson KF, Holmback AM, Groop L, Thorsson O, et al. Impact of exercise intensity and duration on insulin sensitivity in women with T2D. Eur J Intern Med 2010 Oct;21(5):404-8.

(248) Touvra AM, Volaklis KA, Spassis AT, Zois CE, Douda HD, Kotsa K, et al. Combined strength and aerobic training increases transforming growth factor-beta1 in patients with type 2 diabetes. Hormones (Athens ) 2011 Apr;10(2):125-30.

(249) Diedrich A, Munroe DJ, Romano M. Promoting physical activity for persons with diabetes. Diabetes Educ 2010 Jan;36(1):132-40.

(250) Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002 Oct 9;288(14):1723-7.

(251) Keller C, Trevino RP. Effects of two frequencies of walking on cardiovascular risk factor reduction in Mexican American women. Res Nurs Health 2001 Oct;24(5):390-401.

(252) Sopko G, Leon AS, Jacobs DR, Jr., Foster N, Moy J, Kuba K, et al. The effects of exercise and weight loss on plasma lipids in young obese men. Metabolism 1985 Mar;34(3):227-36.

(253) Martyn-Nemeth PA, Vitale GA, Cowger DR. A culturally focused exercise program in Hispanic adults with type 2 diabetes: a pilot study. Diabetes Educ 2010 Mar;36(2):258-67.

(254) Klug C, Toobert DJ, Fogerty M. Healthy Changes for living with diabetes: an evidence-based community diabetes self-management program. Diabetes Educ 2008 Nov;34(6):1053-61.

(255) Boyd ST, Scott DM, Augustine SC. Exercise for low-income patients with diabetes: a continuous quality improvement project. Diabetes Educ 2006 May;32(3):385-93.


(256) Brandon LJ, Gaasch DA, Boyette LW, Lloyd AM. Effects of long-term resistive training on mobility and strength in older adults with diabetes. J Gerontol A Biol Sci Med Sci 2003 Aug;58(8):740-5.

(257) Less LA, Ragoobirsingh D, Morrison EY, Boyne M, Johnson PA. A preliminary report on an assessment of a community-based intervention for diabetes control in adults with type 2 diabetes. Fam Pract 2010 Jun;27 Suppl 1:i46-52. doi: 10.1093/fampra/cmp085. Epub;%2009 Dec 4.:i46-i52.

(258) Lehmann R, Vokac A, Niedermann K, Agosti K, Spinas GA. Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. Diabetologia 1995 Nov;38(11):1313-9.

(259) Zapotoczky H SBHGBBSAPTZH. A controlled study of weight reduction in type 2 diabetics treated by two reinforcers. International Journal of Behavioral Medicine 2001;8(1):42-9.

(260) Trento M, Passera P, Tomalino M, Bajardi M, Pomero F, Allione A, et al. Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up. Diabetes Care 2001 Jun;24(6):995-1000.

(261) Uusitupa M, Laitinen J, Siitonen O, Vanninen E, Pyorala K. The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. Diabetes Res Clin Pract 1993 Mar;19(3):227-38.

(262) Hockaday TD, Hockaday JM, Mann JI, Turner RC. Prospective comparison of modified fat-high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: one year follow-up study. Br J Nutr 1978 Mar;39(2):357-62.

(263) Metz JA, Kris-Etherton PM, Morris CD, Mustad VA, Stern JS, Oparil S, et al. Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet. Am J Clin Nutr 1997 Aug;66(2):373-85.

(264) Milne RM, Mann JI, Chisholm AW, Williams SM. Long-term comparison of three dietary prescriptions in the treatment of NIDDM. Diabetes Care 1994 Jan;17(1):74-80.

(265) Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994 Dec;31(4):215-9.

(266) Pascale RW, Wing RR, Blair EH, Harvey JR, Guare JC. The effect of weight loss on change in waist-to-hip ratio in patients with type II diabetes. Int J Obes Relat Metab Disord 1992 Jan;16(1):59-65.

(267) Wing RR, Epstein LH, Nowalk MP, Koeske R, Hagg S. Behavior change, weight loss, and physiological improvements in type II diabetic patients. J Consult Clin Psychol 1985 Feb;53(1):111-22.


(268) Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994 Oct;97(4):354-62.

(269) Baldi JC, Snowling N. Resistance training improves glycaemic control in obese type 2 diabetic men. Int J Sports Med 2003 Aug;24(6):419-23.

(270) Raz I, Hauser E, Bursztyn M. Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. Isr J Med Sci 1994 Oct;30(10):766-70.

(271) Ronnemaa T, Mattila K, Lehtonen A, Kallio V. A controlled randomized study on the effect of long-term physical exercise on the metabolic control in type 2 diabetic patients. Acta Med Scand 1986;220(3):219-24.

(272) Yeater RA, Ullrich IH, Maxwell LP, Goetsch VL. Coronary risk factors in type II diabetes: response to low-intensity aerobic exercise. W V Med J 1990 Jul;86(7):287-90.

(273) Vanninen E, Uusitupa M, Lansimies E, Siitonen O, Laitinen J. Effect of metabolic control on autonomic function in obese patients with newly diagnosed type 2 diabetes. Diabet Med 1993 Jan;10(1):66-73.

(274) Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C ea. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomizedmulticenter South Danish Diabetes Study. Diabetes Care 2011;34:27-33.

(275) Ligtenberg PC, Hoekstra JB, Bol E, Zonderland ML, Erkelens DW. Effects of physical training on metabolic control in elderly type 2 diabetes mellitus patients. Clin Sci (Lond) 1997 Aug;93(2):127-35.

(276) Fatone C, Guescini M, Balducci S, Battistoni S, Settequattrini A, Pippi R, et al. Two weekly sessions of combined aerobic and resistance exercise are sufficient to provide beneficial effects in subjects with Type 2 diabetes mellitus and metabolic syndrome. J Endocrinol Invest 2010 Jul;33(7):489-95.

(277) Ferrer-Garcia JC, Sanchez LP, Pablos-Abella C, Albalat-Galera R, Elvira-Macagno L, Sanchez-Juan C, et al. [Benefits of a home-based physical exercise program in elderly subjects with type 2 diabetes mellitus]. Endocrinol Nutr 2011 Oct;58(8):387-94.

(278) Campbell DE. Effect of controlled running on serum cholesterol of young adult males of varying morphological constitutions. Res Q 1968 Mar;39(1):47-53.


(279) Gillett PA , aserta MS, hite AT, Martinson L. Responses of 49- to 59-year old sedentary, overweight women to four months of exercise conditioning and/or fitness education. Activities Adapation Aging 1995;19:13-32.

(280) Hagan RD, Upton SJ, Wong L, Whittam J. The effects of aerobic conditioning and/or caloric restriction in overweight men and women. Med Sci Sports Exerc 1986 Feb;18(1):87-94.

(281) Hinkleman LL, Nieman DC. The effects of a walking program on body composition and serum lipids and lipoproteins in overweight women. J Sports Med Phys Fitness 1993 Mar;33(1):49-58.

(282) Hopewell R. The effect of fiber and exercise on weight loss and blood lipids in moderately overweight women. Morgantown, West Virginia: West Virginia University; 1989.

(283) Leon AS, Casal D, Jacobs D, Jr. Effects of 2,000 kcal per week of walking and stair climbing on physical fitness and risk factors for coronary heart disease. J Cardiopulm Rehabil 1996 May;16(3):183-92.

(284) Nieman DC, Brock DW, Butterworth D, Utter AC, Nieman CC. Reducing diet and/or exercise training decreases the lipid and lipoprotein risk factors of moderately obese women. J Am Coll Nutr 2002 Aug;21(4):344-50.

(285) Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988 Nov 3;319(18):1173-9.

(286) Sykes K, eung T, o G. A 12-week prospective randomized controlled trial to investigate the effects of aerobic training on type 2 diabetes patients. Am J Recreation Ther 2004;3:36-42.

(287) Plotnikoff RC, Pickering MA, Glenn N, Doze SL, Reinbold-Matthews ML, McLeod LJ, et al. The effects of a supplemental, theory-based physical activity counseling intervention for adults with type 2 diabetes. J Phys Act Health 2011 Sep;8(7):944-54.

(288) Mathieu ME, Brochu M, Beliveau L. DiabetAction: changes in physical activity practice, fitness, and metabolic syndrome in type 2 diabetic and at-risk individuals. Clin J Sport Med 2008 Jan;18(1):70-5.

(289) Speer EM, Reddy S, Lommel TS, Fischer JG, Heather S, Park S, et al. Diabetes self-management behaviors and A1c improved following a community-based intervention in older adults in Georgia senior centers. J Nutr Elder 2008;27(1-2):179-200.


(290) Boudou P, de KE, Vexiau P, Fiet J, Cathelineau G, Gautier J. Effects of a single bout of exercise and exercise training on steroid levels in middle-aged type 2 diabetic men: relationship to abdominal adipose tissue distribution and metabolic status. Diabetes Metab 2000 Dec;26(6):450-7.

(291) Fujii S, Okuno Y, Okada K, Tanaka S, Seki J, Wada M, et al. Effects of physical training on glucose tolerance and insulin response in diabetics. Osaka City Med J 1982;28(1):1-8.

(292) Khan S, Rupp J. The effect of exercise conditioning, diet, and drug therapy on glycosylated hemoglobin levels in type 2 (NIDDM) diabetics. J Sports Med Phys Fitness 1995 Dec;35(4):281-8.

(293) Yamanouchi K, Shinozaki T, Chikada K, Nishikawa T, Ito K, Shimizu S, et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 1995 Jun;18(6):775-8.

(294) Heller SR, Clarke P, Daly H, Davis I, McCulloch DK, Allison SP, et al. Group education for obese patients with type 2 diabetes: greater success at less cost. Diabet Med 1988 Sep;5(6):552-6.

(295) Korhonen T, Uusitupa M, Aro A, Kumpulainen T, Siitonen O, Voutilainen E, et al. Efficacy of dietary instructions in newly diagnosed non-insulin-dependent diabetic patients. Comparison of two different patient education regimens. Acta Med Scand 1987;222(4):323-31.

(296) Pissarek D, Panzram G, Lundershausen R, Adolph W, Senf L. [Intensified therapy of newly detected maturity onset diabetes]. Endokrinologie 1980 Jan;75(1):105-15.

(297) Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, et al. Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 2002 Sep;34(9):509-15.

(298) Wing RR, pstein LH, owalk MP, cott N, Koeske R, agg S. Does self-monitoring of blood glucose levels improve dietary compliance for obese patients with type II diabetes? American Journal of Medicine 1986;81(5):830-6.

(299) Wing RR, arcus MD, alata R, Epstein LH, Miaskiewicz S, lair EH. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Archives of Internal Medicine 1991;151(7):1334-40.

(300) Wing RR, Marcus MD, Epstein LH, Jawad A. A "familybased" approach to the treatment of obese type II diabetic patients. Journal of Consulting and Clinical Psychology 1991;59(1):156-62.

ars.els-cdn.com€¦ · Web view(203) Támez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB....

Documents

Transcript of ars.els-cdn.com€¦ · Web view(203) Támez Pérez HE, Gómez de Ossio MD, Ibarra Martínez IB....